Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| all enrolled patients | All patient who signed the consent form for participation to the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Linperlisib | Drug | 80 mg, qd |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of adverse events (AEs)/ serious adverse events (SAEs) | Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with lymphoma receiving linperlisib therapy | up to 4 weeks after the last dose |
| Measure | Description | Time Frame |
|---|---|---|
| Complete response rate | Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria. | 6 months |
| Progression-free survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Clinical diagnosis of lymphoma
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Weili Zhao | Contact | +862164370045 | 610707 | zwl_trial@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | China |
The safty of Linperlisib in lymphoma patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
| 1 years and 2 years |
| Overall survival | Overall survival was defined as the time from the date of enrollment to the date of death from any cause. | Baseline up to data cut-off (up to approximately 2 years) |
| Duration of response | Duration of response was defined as the time from the date of favorable response until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria | Baseline up to data cut-off (up to approximately 2 years) |
| Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital | Tianjin | China |
|